Inovio Pharmaceuticals, Inc
INOVIO Pharmaceuticals is a clinical-stage biotechnology company developing DNA medicines designed to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases. Its platform combines proprietary DNA constructs with the CELLECTRA delivery device to enable the body to produce disease-fighting proteins, but the company has not yet commercialized any approved product.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueClinical-stage DNA therapeutics and vaccines intended to treat or prevent HPV-related disease, cancer, and infections.
Proprietary electroporation delivery system used to administer the company's DNA medicines.
License fees, milestone payments, and research collaboration revenue from partners and government contracts.
Customers
The company does not yet have commercial product customers because it has no approved products and no sales organization. Current revenue comes mainly from collaboration partners, licensees, and government or research organizations that fund development work. If approved, its future customers would likely be specialty physicians, hospitals, and treatment centers in defined disease areas such as HPV-related disease, oncology, and infectious disease.
Biopharma and research partners that pay for access to technology, development work, milestones, or joint programs.
Agencies and institutes that fund or co-develop programs through grants, contracts, and research collaborations.
Potential future buyers of approved DNA medicines for HPV-related disease, cancer, or infectious disease.
Potential future sites of care that would administer approved products if commercialization succeeds.
Strategy
The company is concentrating resources on advancing INO-3107 toward potential U.S. approval and a possible launch in 2026 while extending cash runway. It is also prioritizing collaborations and third-party commercialization arrangements outside the United States to reduce the need to build a global sales force from scratch.
This is the company's most advanced candidate and the clearest path to first product revenue.
The company expects continued losses and needs to preserve liquidity to reach key clinical and regulatory milestones.
The company lacks a full sales force and intends to use third parties, especially outside the U.S., to commercialize approved products.
Geography
INOVIO is headquartered in the United States and manufactures its CELLECTRA device in San Diego. Its current business is largely U.S.-centric, but it also relies on foreign collaborators, foreign regulatory pathways, and key foreign markets for patent protection and future commercialization.
Risks
INOVIO remains a pre-revenue biotechnology company with substantial execution, financing, and regulatory risk. Its future depends on successful clinical development, approval, manufacturing reliability, partner execution, and the ability to raise additional capital before cash is exhausted.
- Need for additional capitalImpact: CriticalLikelihood: High
The company expects continued operating losses and says current cash will not fund development and commercialization needs.
Exposure: Could dilute shareholders or constrain operations if financing is unavailable.
- Going-concern uncertaintyImpact: CriticalLikelihood: High
Management disclosed substantial doubt about the ability to continue as a going concern beyond the second quarter of 2026.
Exposure: Financial statement and operational continuity risk.
- Clinical and regulatory failureImpact: HighLikelihood: High
All candidates remain in R&D and require extensive testing and approval before any product sales.
Exposure: INO-3107 and other pipeline assets.
- China-related operational exposureImpact: HighLikelihood: High
The company has collaborations with Chinese companies and may rely on clinical materials manufactured in China.
Exposure - Manufacturing and supply concentrationImpact: HighLikelihood: Medium
The company has single-source suppliers for certain molded plastic parts, machined metal parts, and PCBs.
Exposure: CELLECTRA device production and launch readiness.
- Intellectual property disputesImpact: MediumLikelihood: Low
Biotech competition and patent enforcement can be expensive and may limit freedom to operate.
Exposure: Platform technology and product candidates.
Accounting
Judgemental itemsRevenue is derived from license fees, milestones, and collaborative R&D agreements, so recognition depends on contract terms and performance obligations.
Impact: Can cause lumpy quarterly revenue and limited comparability.
R&D expenses require estimates for trial services received but not yet invoiced.
Impact: Can materially shift reported operating losses between periods.
Management disclosed substantial doubt about continuing operations beyond Q2 2026.
Impact: Important for liquidity analysis and financial statement interpretation.
The company disclosed minimum purchase obligations under supply agreements.
Impact: Affects near-term cash needs and disclosure of contractual commitments.
Similar listed companies
Publicly listed companies with a comparable business focus.
IO Biotech, Inc.
IOBTQ · Pharmaceutical Preparations
INVO Fertility, Inc.
IVF · Surgical & Medical Instruments & Apparatus
IN8bio, Inc
INAB · Biological Products, (No Diagnostic Substances)
Innoviva, Inc.
INVA · Pharmaceutical Preparations
Phio Pharmaceuticals Corp.
PHIO · Pharmaceutical Preparations
LeonaBio, Inc.
LONA · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026